[F18]EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Carcinoma of the Cervix
- To determine if the presence and heterogeneity of hypoxia can be detected by fluorine F
18 EF5 binding in tumors during PET/CT imaging in patients with newly diagnosed or
recurrent carcinoma of the cervix.
- To determine if fludeoxyglucose F 18 uptake correlates with fluorine F 18 EF5 uptake.
- To assess the relationship between fluorine F 18 EF5 uptake and disease-free and
OUTLINE: Patients are stratified according to disease stage (locally advanced vs recurrent
or metastatic disease).
Patients receive fluorine F 18 EF5 IV followed by PET/CT imaging from the base of skull to
upper thigh at baseline and during radiotherapy or chemotherapy (i.e., at 3-4 weeks after
the initiation of radiotherapy or after the 4th, 5th, or 6th course of chemotherapy).
Patients also undergo fludeoxyglucose F 18 PET/CT imaging within 7 to 10 days of the second
fluorine F 18 EF5 scan.
After completion of study treatment, patients are followed up at 30 days and then annually
Masking: Open Label, Primary Purpose: Diagnostic
PET imaging of tumor hypoxia, defined by the maximum standard uptake value and by the tumor to muscle ratio
Lilie Lin, MD
Abramson Cancer Center of the University of Pennsylvania
|Abramson Cancer Center of the University of Pennsylvania||Philadelphia, Pennsylvania 19104-4283|